HAE Haemonetics Corp

Price (delayed)

$60.07

Market cap

$3.06B

P/E Ratio

38.26

Dividend/share

N/A

EPS

$1.57

Enterprise value

$3.58B

Highlights
The price to earnings (P/E) is 76% lower than the 5-year quarterly average of 162.3 and 29% lower than the last 4 quarters average of 53.7
The equity is up by 25% year-on-year
The company's quick ratio fell by 27% QoQ but it rose by 15% YoY
The company's EPS fell by 27% QoQ but it rose by 4% YoY
The debt has soared by 128% since the previous quarter and by 85% year-on-year
The company's gross profit fell by 18% YoY and by 7% QoQ

Key stats

What are the main financial stats of HAE
Market
Shares outstanding
50.95M
Market cap
$3.06B
Enterprise value
$3.58B
Valuations
Price to earnings (P/E)
38.26
Price to book (P/B)
4.17
Price to sales (P/S)
3.5
EV/EBIT
39.85
EV/EBITDA
20.55
EV/Sales
4.11
Earnings
Revenue
$870.46M
EBIT
$89.75M
EBITDA
$174.03M
Free cash flow
$73.58M
Per share
EPS
$1.57
Free cash flow per share
$1.45
Book value per share
$14.4
Revenue per share
$17.17
TBVPS
$19.49
Balance sheet
Total assets
$1.82B
Total liabilities
$1.09B
Debt
$707.61M
Equity
$731.67M
Working capital
$440.05M
Liquidity
Debt to equity
0.97
Current ratio
2.74
Quick ratio
1.26
Net debt/EBITDA
2.96
Margins
EBITDA margin
20%
Gross margin
45.7%
Net margin
9.1%
Operating margin
10.3%
Efficiency
Return on assets
5.3%
Return on equity
11.7%
Return on invested capital
9%
Return on capital employed
5.7%
Return on sales
10.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HAE stock price

How has the Haemonetics stock price performed over time
Intraday
2.84%
1 week
9.06%
1 month
0.67%
1 year
-32.67%
YTD
-49.41%
QTD
-45.89%

Financial performance

How have Haemonetics's revenue and profit performed over time
Revenue
$870.46M
Gross profit
$397.84M
Operating income
$89.75M
Net income
$79.47M
Gross margin
45.7%
Net margin
9.1%
The operating income is down by 34% since the previous quarter and by 13% year-on-year
The operating margin has contracted by 34% from the previous quarter
HAE's net income is down by 27% since the previous quarter but it is up by 3.8% year-on-year
The net margin is down by 25% since the previous quarter but it is up by 18% year-on-year

Growth

What is Haemonetics's growth rate over time

Valuation

What is Haemonetics stock price valuation
P/E
38.26
P/B
4.17
P/S
3.5
EV/EBIT
39.85
EV/EBITDA
20.55
EV/Sales
4.11
The price to earnings (P/E) is 76% lower than the 5-year quarterly average of 162.3 and 29% lower than the last 4 quarters average of 53.7
The company's EPS fell by 27% QoQ but it rose by 4% YoY
The price to book (P/B) is 44% lower than the last 4 quarters average of 7.5 and 33% lower than the 5-year quarterly average of 6.2
The equity is up by 25% year-on-year
The stock's P/S is 39% less than its last 4 quarters average of 5.7 and 20% less than its 5-year quarterly average of 4.4
The revenue fell by 12% YoY

Efficiency

How efficient is Haemonetics business performance
The company's return on invested capital fell by 40% QoQ and by 22% YoY
The company's return on sales fell by 34% QoQ
The company's return on assets fell by 34% QoQ and by 15% YoY
HAE's return on equity is down by 30% since the previous quarter and by 11% year-on-year

Dividends

What is HAE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HAE.

Financial health

How did Haemonetics financials performed over time
The total assets is 67% more than the total liabilities
The total liabilities has soared by 82% from the previous quarter and by 60% YoY
The total assets has grown by 44% YoY and by 38% from the previous quarter
The debt is 3.3% smaller than the equity
The debt has soared by 128% since the previous quarter and by 85% year-on-year
The debt to equity has soared by 126% from the previous quarter and by 49% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.